Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan

NCT00212693 Phase 2 COMPLETED

The purpose of this study is to evaluate the efficacy and safety of ONO-2506PO in patients with Parkinson's Disease

Details

Lead sponsor	Ono Pharmaceutical Co., Ltd.
Phase	Phase 2
Status	COMPLETED
Enrolment	165
Start date	2004-01

Conditions

• Parkinson's Disease

Interventions

• ONO-2506PO

Primary outcomes

• Unified Parkinson's disease rating scale (Part III)